Details for New Drug Application (NDA): 050617
✉ Email this page to a colleague
NDA 050617 describes ERYGEL, which is a drug marketed by Mylan and is included in one NDA. Additional details are available on the ERYGEL profile page.
The generic ingredient in ERYGEL is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
The generic ingredient in ERYGEL is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
Summary for 050617
| Tradename: | ERYGEL |
| Applicant: | Mylan |
| Ingredient: | erythromycin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050617
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GEL;TOPICAL | Strength | 2% | ||||
| Approval Date: | Oct 21, 1987 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
